{"nctId":"NCT00441350","briefTitle":"Olmesartan/HCTZ 40/12.5 mg Combination Therapy Versus Olmesartan Medoxomil 40 mg Monotherapy in Essential Hypertension","startDateStruct":{"date":"2007-07"},"conditions":["Hypertension"],"count":1004,"armGroups":[{"label":"OM 40","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: OM 40"]},{"label":"OM/HCTZ 40/12.5","type":"EXPERIMENTAL","interventionNames":["Drug: OM/HCTZ 40/12.5"]}],"interventions":[{"name":"OM 40","otherNames":["Treatment"]},{"name":"OM/HCTZ 40/12.5","otherNames":["Treatment"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients with a diagnosis of essential hypertension, either treatment-naive or including currently on anti-hypertensive medication (in Italy only treatment naive patients) in whom it is medically justifiable to withdraw treatment , and who are likely to meet the required BP inclusion criteria at randomisation:\n\n  * Mean sitting dBP ≥ 100 mmHg and ≤ 120 mmHg.\n  * Mean sitting sBP ≥ 160 mmHg and ≤ 200 mmHg.\n\nMain Exclusion Criteria:\n\n* Mean sitting sBP values \\> 200 mmHg and/or dBP \\> 120 mmHg.\n* Pregnant or nursing women.\n* Patients with serious disorders which may limit the ability to evaluate the efficacy or safety of the tested medication, including cerebrovascular, cardiovascular, renal, respiratory, hepatic, gastrointestinal, endocrine or metabolic, haematological, oncological, neurological, and psychiatric diseases. The same applies for immunocompromised and/or neutropenic patients.\n* Patients with secondary hypertension of any aetiology such as renal disease, pheochromocytoma, or Cushing's syndrome.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"dBP Change After 8 Weeks Phase A","description":"Reduction in Mean Trough Sitting dBP (mmHg) from Baseline (Week 0) to Week 8","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-15.8","spread":"9.71"},{"groupId":"OG001","value":"-18.9","spread":"9.32"}]}]}]},{"type":"PRIMARY","title":"sBP Change After 8 Weeks Phase A","description":"Reduction in Mean Trough Sitting sBP (mmHg) from Baseline (Week 0) to Week 8","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-26.5","spread":"14.56"},{"groupId":"OG001","value":"-31.9","spread":"14.76"}]}]}]},{"type":"SECONDARY","title":"dBP Change After 8 Weeks Phase B","description":"Reduction in trough sitting diastolic blood pressure after 8 weeks of additional treatment, depending on Phase A treatment and outcome (responder/non-responder).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"6.95"},{"groupId":"OG001","value":"-9.3","spread":"7.91"},{"groupId":"OG002","value":"-0.3","spread":"6.68"},{"groupId":"OG003","value":"-8.0","spread":"8.56"}]}]}]},{"type":"SECONDARY","title":"sBP Change After 8 Weeks Phase B","description":"Reduction in trough sitting systolic blood pressure after 8 weeks of additional treatment, depending on Phase A treatment and outcome (responder/non-responder).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.5","spread":"6.95"},{"groupId":"OG001","value":"-12.4","spread":"11.64"},{"groupId":"OG002","value":"-0.4","spread":"9.32"},{"groupId":"OG003","value":"-12.1","spread":"12.69"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":188},"commonTop":["Nasopharyngitis","Headache","Bronchitis","Dizziness","Cough"]}}}